Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alembic Pharma gets...

    Alembic Pharma gets USFDA nod for Clonazepam orally disintegrating tablets

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-01T12:25:58+05:30  |  Updated On 16 Aug 2021 4:07 PM IST

    The approval from the United States Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Clonazepam orally disintegrating tablets, in the strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg, Alembic Pharmaceuticals said in a filing to BSE.


    New Delhi: Drug firm Alembic Pharmaceuticals Monday said it has received approval from the US health regulator for Clonazepam orally disintegrating tablets, used for the treatment of seizures.


    The approved product is therapeutically equivalent to the reference listed drug Klonopin orally disintegrating tablets of Hoffmann-La Roche, Inc.


    Also Read: Alembic Pharma gets USFDA nod for generic version of Tamiflu capsules










    The approval from the United States Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Clonazepam orally disintegrating tablets, in the strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg, Alembic Pharmaceuticals said in a filing to BSE.








    Quoting IQVIA data, Alembic Pharma said Clonazepam orally disintegrating tablets USP has an estimated market size of USD 20 million for 12 months ending December 2018.


    Clonazepam orally disintegrating tablet is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures.


    The company currently has a total of 98 ANDA approvals (86 final approvals and 12 tentative approvals) from USFDA, it added.


    Also Read: Alembic Pharma clears USFDA inspection at oncology unit in Panelav

    Alembic PharmaBenzodiazepineChemical compoundsChloroarenesClonazepamGenentechHoffmann-La RocheKlonopinLactamsOrally disintegrating tabletpharmapharma newspharma news indiaPharmaceutical industryPsychoactive drugsRTTseizures drugUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok